王悦

    【摘要】 目的：探討重组人血管内皮抑制素注射液联合顺铂胸腔灌注治疗肺癌恶性胸腔积液的效果及对免疫球蛋白的影响。方法：选取2019年1月-2020年1月民航总医院收治的94例肺癌恶性胸腔积液患者，按照其治疗方法的异同将其分组，将接受重组人血管内皮抑制素注射液联合顺铂胸腔灌注治疗的患者划分为观察组(n=47)，将接受单纯顺铂胸腔灌注治疗的患者划分为对照组(n=47)。比较两组患者的治疗有效率、疾病控制率、生存质量评分、血清相关指标及免疫球蛋白指标。结果：观察组的治疗有效率及疾病控制率均高于对照组(P0.05)；治疗21 d，两组各维度生存质量评分均高于治疗前，且观察组均高于对照组(P0.05)；治疗21 d，两组HIF-1α、VEGF、PKM2均低于治疗前，且观察组均低于对照组(P0.05)；治疗21 d，两组IgA、IgG、IgM均高于治疗前，且观察组均高于对照组(P0.05); after 21 d of treatment， quality of life scores of all dimensions of both groups were higher than those before treatment， those of the observation group were higher than those of the control group (P0.05); after 21 d of treatment， HIF-1α， VEGF and PKM2 of both groups were lower than those before treatment， those of observation group were lower than those of control group (P0.05); after 21 d of treatment， IgA， IgG and IgM of both groups were higher than those before treatment ......